logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

NSCLC: FDA approves a liquid biopsy, NGS combo to determine EGFR mutations

Approval is specific only to identifying EGFR mutations in patients likely to benefit from osimertinib.